A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer

Metastatic Breast Cancer Clinical Trial

— TH V THL  

Official title:

A Phase III Randomized Study of TH (Paclitaxel and Trastuzumab) Versus THL (Paclitaxel, Trastuzumab and Lapatinib) in First Line Treatment of HER2-positive Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01526369
• Other study ID #: CTRIAL-IE (ICORG) 11-10
• Status: Completed
• Phase: Phase 3
• Start date: February 13, 2012
• Est. completion date: February 17, 2023

Study information

• Verified date: April 2023
• Source: Cancer Trials Ireland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed phase III randomised trial will compare the efficacy of trastuzumab and paclitaxel with trastuzumab, paclitaxel and lapatinib in first line treatment of HER2 positive metastatic breast cancer. The investigators will also examine potential predictive biomarkers of response to trastuzumab and lapatinib in pre-treatment biopsy samples and serum samples.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 75
• Est. completion date: February 17, 2023
• Est. primary completion date: November 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent obtained prior to any study-related procedures

2. Female age 18 years or greater.

3. ECOG Performance Status of 0 or 1.

4. Histologically or cytologically-confirmed invasive metastatic breast cancer.

5. Patients must have measurable disease according to RECIST criteria Version 1.1, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan,MRI, or calipers by clinical exam.

6. Tumour shows HER2 over-expression (3+ by IHC and/or FISH + ) by testing of the primary tumour and if available the biopsied metastatic lesion

7. Patients who received prior radiotherapy must have completed it at least 4 weeks before registration and recovered from all treatment-related toxicities.

8. Cardiac ejection fraction within the institutional range of normal as measured by MUGA or ECHO within 14 days prior to registration. Note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution.

9. Adequate haematological, hepatic, and renal function.

• Haemoglobin = 9g/dL
• Neutrophils (ANC/AGC) =1500/mm³ (1.5 x 10^9/L)
• Platelets = (100 x 10^9/L)
• Total bilirubin = 1.5mg/dL (25.65 µmol/L)
• Both ALT (SGPT) and AST (SGOT) = 3 x ULN with or without liver Metastasis
• Alkaline phosphatase = 2.5 x ULN
• Serum creatinine =1.5 ULN or calculated creatinine clearance (CrCl) = 30mL/min according to the Cockcroft and Gault formula (Appendix K)

10. Able to swallow and retain oral medication.

11. Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Female patients of childbearing potential must have pregnancy excluded by urine or serum beta-HCG testing within 7 days prior to registration.

12. Estimated life expectancy greater than 12 weeks

Exclusion Criteria:

1. Prior systemic therapy for metastatic disease (except one line of hormonal therapy for metastatic disease without trastuzumab).

2. Recurrence within 12 months from completion of adjuvant chemotherapy to the development of metastatic disease.

3. Recurrence within 6 months from completion of adjuvant trastuzumab to the development of metastatic disease.

4. Prior lapatinib treatment.

5. Peripheral neuropathy = grade 2

6. Patients with known CNS metastasis should be excluded from this clinical trial

7. Prior radiotherapy to more than half of the bony pelvis.

8. Uncontrolled or symptomatic angina, uncontrolled arrhythmias, congestive heart failure, a documented MI within 6 months prior to registration or any other cardiac disorders, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient .

9. Immediate or delayed hypersensitivity or untoward reaction to paclitaxel, trastuzumab, or other related compounds, or to drugs chemically related to lapatinib (including other anilinoquinazolines, e.g. gefitinib (Iressa®) and erlotinib (Tarceva®), or other chemically-related compounds).

10. Pregnant or breastfeeding women are excluded from this study.

11. Patients should not be receiving any other investigational agents (within 30 days prior to registration) or receiving concurrent anticancer therapy.

12. Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors (Table 9).

13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements.

14. Patients with GI tract disease resulting in an inability to take oral medication, malabsorption syndrome, a requirement for IV alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).

15. Have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)

16. Concurrent treatment with ovarian hormone replacement therapy. Prior treatment must be stopped prior to registration.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Trastuzumab

• Paclitaxel

• Lapatinib

Locations

Country	Name	City	State
Finland	Helsinki University Hopsital	Helsinki
Finland	Kuopio University hospital	Kuopio
France	CRLC Val d'Aurelle	Montpellier
Germany	Interdisziplinäre Onkologische Zentrum München (IOZ München)	Munich
Ireland	Cork University Hospital	Cork
Ireland	Beaumont Hospital	Dublin
Ireland	Mater Misericordiae University Hospital	Dublin
Ireland	Mater Private Hospital	Dublin
Ireland	St James's Hospital	Dublin
Ireland	St Vincent's University Hospital	Dublin	Leinster
Ireland	University Hospital Galway	Galway
Ireland	Midwestern Regional Hospital	Limerick
Ireland	Sligo General Hospital	Sligo
Ireland	Waterford Regional Hospital	Waterford
Israel	Rabin Medical Center	Petah Tikva
Israel	The Chaim Sheba Medical Center	Tel Hashomer
Norway	Oslo University Hopsital	Oslo
Portugal	Hospital Santa Maria	Lisbon
Spain	Centro Oncologico de Galicia	A Coruña
Spain	Hospital Nuestra Senora de Sonsoles	Avila
Spain	Hospital Infanta Cristina	Badajoz
Spain	Hospital Virgen de la Luz	Cuenca
Spain	Hospital General de Grannollers	Granollers
Spain	Complejo Hospitalario de Jaen	Jaén
Spain	Hospital Universitari Arnau de Vilanova de Lleida	Lleida
Spain	Complejo Hospitalario Xeral Calde / Hospital Lucus Augusti	Lugo
Spain	H. Puerta de Hierro	Madrid
Spain	Hospital General Universitario Gregorio Maranon	Madrid
Spain	Hospital de Mataro	Mataro
Spain	Hospital Infanta Cristina	Parla
Spain	Hospital Donostia	San Sebastián
Spain	Hospital Universitario de Canarias	Santa Cruz De Tenerife
Spain	Hospital General Universitario de Elche	Valencia
Spain	Hospital General Universitario de Valencia	Valencia
Spain	Hospital Clinico Universitario 'Lozano Blesa'	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Cancer Trials Ireland

Countries where clinical trial is conducted

Finland,  France,  Germany,  Ireland,  Israel,  Norway,  Portugal,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression Free Survival		9 months
Secondary	Overall Survival		30 months